Pipeline
Our monoclonal antibodies have a multitude of addiction related indications, including treatment of opioid use disorder, smoking cessation and acute cannabis overdose
Program
Indication
Preclincal
CMC & Tox
Phase 1
Phase 2
Milestone
CSX-1004
mAb subcutaneous
Fentanyl Overdose Prevention
Phase 1 complete 2Q 2024
Phase 2 initiate 1Q 2025
CSX-1004 (sBLA)
mAb subcutaneous
Opioid Use Disorder
Phase 2 initiate 2H 2025
CSX-3002
mAb subcutaneous
Smoking Cessation
Lead optimization
CSX-5000
mAb infusion
Acute Cannabis Overdose
Lead optimization
CSX-1004 is a human monoclonal antibody directed against fentanyl and fentanyl analogs. It is being developed as a fixed-dose subcutaneous injection that for prophylaxis against overdose from fentanyl and fentanyl analogs. CSX-1004 is a Phase 2 ready molecule. CSX-1004 is also being evaluated for treatment of Opioid Use Disorder (OUD).
CSX-3002 is a monoclonal antibody being developed for the treatment of nicotine addiction, an area of high unmet need for additional safe and effective treatments. We have generated several high-affinity antibodies to nicotine, which are able to block nicotine’s effects in mice. Current studies are examining the efficacy of CSX-3002 in disrupting the behavioral effects of nicotine in rats.
Cessation is currently investigating several monoclonal antibody candidates against THC as well as synthetic cannabinoids. Antibodies generated in this program would offer treatment of acute overdose for which there is currently no approved medications.
Program
CSX-1004
mAb subcutaneous
Indication
Fentanyl Overdose Prevention
Preclinical
CMC & Tox
Phase 1
Phase 2
Milestone
Phase 1 complete 2Q 2024
Phase 2 initiate 1Q 2025
Program
CSX-1004 (sBLA)
mAb subcutaneous
Indication
Opioid Use Disorder
Preclinical
CMC & Tox
Phase 1
Phase 2
Milestone
Phase 2 initiate 2H 2025
Program
CSX-3002
mAb subcutaneous
Indication
Smoking Cessation
Preclinical
CMC & Tox
Phase 1
Phase 2
Milestone
Lead optimization
Program
CSX-5000
mAb infusion
Indication
Acute Cannabis Overdose
Preclinical
CMC & Tox
Phase 1
Phase 2
Milestone
Lead optimization
CSX-1004 is a human monoclonal antibody directed against fentanyl and fentanyl analogs. It is being developed as a fixed-dose subcutaneous injection that for prophylaxis against overdose from fentanyl and fentanyl analogs. CSX-1004 is a Phase 2 ready molecule. CSX-1004 is also being evaluated for treatment of Opioid Use Disorder (OUD).
CSX-3002 is a monoclonal antibody being developed for the treatment of nicotine addiction, an area of high unmet need for additional safe and effective treatments. We have generated several high-affinity antibodies to nicotine, which are able to block nicotine’s effects in mice. Current studies are examining the efficacy of CSX-3002 in disrupting the behavioral effects of nicotine in rats.
Cessation is currently investigating several monoclonal antibody candidates against THC as well as synthetic cannabinoids. Antibodies generated in this program would offer treatment of acute overdose for which there is currently no approved medications.